Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News AC Immune SA ACIU

Healthcare Biotechnology
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded... see more

Recent & Breaking News (NDAQ:ACIU)

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease

GlobeNewswire December 11, 2025

AC Immune to Present at the Jefferies 2025 London Healthcare Conference

GlobeNewswire November 11, 2025

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

GlobeNewswire November 4, 2025

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board

GlobeNewswire October 28, 2025

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine

GlobeNewswire October 24, 2025

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine

GlobeNewswire September 25, 2025

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway

GlobeNewswire September 4, 2025

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

GlobeNewswire August 5, 2025

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

GlobeNewswire April 30, 2025

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

GlobeNewswire April 2, 2025

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD(TM) 2025

GlobeNewswire March 25, 2025

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

GlobeNewswire March 13, 2025

AC Immune to Participate in Upcoming Investor Conferences

GlobeNewswire March 4, 2025

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

GlobeNewswire December 10, 2024

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

GlobeNewswire November 14, 2024

AC Immune to Present at the Jefferies 2024 London Healthcare Conference

GlobeNewswire November 13, 2024

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire November 5, 2024

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease

GlobeNewswire September 17, 2024

AC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

GlobeNewswire August 28, 2024

AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire August 6, 2024

Podcasts